LewisDaKat
Sep 30, 4:30 PM
$LB Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
https://marketwirenews.com/stock/lb/news/merck-s-tulisokibart-met-primary-and-key-secondary-e-7280369164036262.html?utm_source=stocktwits
0 replies